Yahoo · Nov 1, 2026
Eli Lilly stock surges as cheaper drugs unlock a bigger market
Lilly shares hit a record as weight-loss drugs became more accessible.
NYSE · LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General
$1,417.54
Up+$43.84 (+3.19%)
Updated Nov 1, 2026, 5:25 PM
SID Score
7.0/10
Composite research score
Smart Money
44/100
Neutral
- Market cap
- 906.5B
- P/E ratio
- 49.16
- Dividend yield
- 0.55%
- 52-week range
- $850.51 – $1,449.68
- Volume
- 5.25M
- Avg. volume
- 3.8M
Price performance · LLY
LLY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LLY closed at $1,417.54 after 20 trading sessions, up 24.01% for the selected period.
- Last close
- $1,417.54
- Period change
- +24.01%
- Period low
- $1,143.12
- Period high
- $1,417.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1,428.83 | $1,449.68 | $1,408.36 | $1,417.54 | 5.25M |
| Oct 29, 2026 | $1,332.73 | $1,408.38 | $1,330.00 | $1,373.70 | 4.37M |
| Oct 28, 2026 | $1,268.55 | $1,299.43 | $1,260.34 | $1,288.30 | 2.06M |
| Oct 27, 2026 | $1,273.50 | $1,297.92 | $1,272.0703 | $1,281.91 | 1.85M |
| Oct 26, 2026 | $1,286.39 | $1,296.90 | $1,273.7293 | $1,279.14 | 2.11M |
| Oct 23, 2026 | $1,304.15 | $1,307.9199 | $1,257.62 | $1,273.46 | 2.28M |
| Oct 22, 2026 | $1,281.76 | $1,321.21 | $1,275.10 | $1,306.69 | 2.66M |
| Oct 21, 2026 | $1,266.905 | $1,279.28 | $1,261.08 | $1,270.75 | 1.88M |
| Oct 20, 2026 | $1,263.50 | $1,311.75 | $1,260.17 | $1,283.66 | 2.97M |
| Oct 19, 2026 | $1,243.39 | $1,259.75 | $1,239.10 | $1,240.34 | 1.96M |
| Oct 16, 2026 | $1,256.00 | $1,274.56 | $1,251.25 | $1,257.03 | 2.41M |
| Oct 15, 2026 | $1,235.04 | $1,275.88 | $1,230.66 | $1,251.61 | 3.76M |
| Oct 14, 2026 | $1,177.87 | $1,216.714 | $1,174.24 | $1,208.74 | 3.17M |
| Oct 13, 2026 | $1,190.70 | $1,193.30 | $1,158.405 | $1,166.51 | 1.84M |
| Oct 12, 2026 | $1,181.24 | $1,188.70 | $1,172.805 | $1,182.62 | 1.25M |
| Oct 9, 2026 | $1,153.56 | $1,179.82 | $1,151.67 | $1,179.27 | 1.39M |
| Oct 8, 2026 | $1,183.50 | $1,186.0903 | $1,131.21 | $1,169.60 | 3.09M |
| Oct 7, 2026 | $1,173.62 | $1,206.63 | $1,166.00 | $1,188.72 | 2.31M |
| Oct 6, 2026 | $1,147.15 | $1,177.065 | $1,139.98 | $1,157.49 | 2.13M |
| Oct 5, 2026 | $1,150.76 | $1,165.73 | $1,139.495 | $1,143.12 | 1.98M |
Latest LLY news
The latest Smart Investors Daily articles mentioning LLY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LLY research
Overview
Company profile and research snapshot.
Company profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1,055.92
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Wells Fargo | Overweight | — |
| Oct 30, 2026 | Morgan Stanley | Overweight | — |
| Oct 30, 2026 | Scotiabank | Sector Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 31, 2026
After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?
Eli Lilly stock is trading at a record high.
Yahoo · Oct 31, 2026
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.
Yahoo · Oct 31, 2026
Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations”
Key TakeawaysEli Lilly’s Q3 revenue rose 39% to $24. 4 billion, and Mounjaro and Zepbound brought in about $16.
AI research layers
Interpretive context generated from the platform’s current data sources.
Eli Lilly and Company Stock Performance
Eli Lilly and Company shares traded at $1,417.54, reflecting a single-session decline of 1.66% per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum across longer timeframes, gaining 23.28% over the past month, 26.41% over three months, and 33.22% year-over-year according to Massive/Polygon data. LLY currently trades well above both its 50-day moving average of $1,197.14 and its 200-day moving average of $1,088.35, representing premiums of approximately 18.4% and 30.2% respectively. The 14-day relative strength index stands at 79.9, placing the stock firmly in overbought territory above the conventional 70 threshold. Average daily trading volume registers at approximately 3.80 million shares. The company maintains a market capitalization of approximately $906.5 billion. Notably, LLY carries a beta of 0.369 per SID market data, indicating substantially lower volatility relative to the broader market.
Eli Lilly and Company Valuation Analysis
Eli Lilly and Company currently trades at a price-to-earnings ratio of 49.16, a significant premium to the broader Healthcare sector, reflecting investor expectations for sustained high growth according to SID market data. The PEG ratio stands at 1.47, suggesting the stock is trading modestly above a growth-adjusted fair value benchmark of 1.0, though it remains below levels typically considered significantly overvalued. The price-to-book ratio registers at 38.04, underscoring the market's valuation of Lilly's intangible assets, including its pharmaceutical pipeline and brand equity, per SEC filings. The company offers a dividend yield of approximately 0.59%, a relatively modest return that reflects the firm's prioritization of reinvestment in research and development over shareholder distributions. With a market capitalization of $906.5 billion, Eli Lilly ranks among the most highly valued companies in the global healthcare industry, driven largely by its GLP-1 receptor agonist franchise.
Smart Money Activity for LLY
Eli Lilly and Company registers an overall smart money score of 44 out of 100, signaling a neutral stance among sophisticated market participants according to SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained interest from large asset managers per 13F institutional filings. In contrast, the insider trading component scores 7.1 out of 25, with SEC Form 4 filings revealing 13 insider transactions over the past 90 days, comprising 8 purchases and 5 sales. The net insider buying suggests modest confidence among company executives and directors at current price levels. The dark pool activity score stands at 9.0 out of 25, reflecting moderate off-exchange trading interest. Congressional trading activity scores a low 3.2 out of 25, indicating limited recent disclosed trading by members of Congress. The divergence between strong institutional conviction and more subdued insider and congressional activity creates a mixed signal profile for LLY at its current elevated valuation levels.
Eli Lilly and Company Earnings Outlook
Eli Lilly and Company has delivered a consistent pattern of earnings beats across its three most recently reported quarters according to company earnings reports. The most recent reported quarter posted earnings per share of $7.48 against an analyst consensus estimate of $6.36, representing a positive surprise of $1.12. The prior quarter delivered an even more pronounced beat, with actual EPS of $8.38 versus estimates of $6.01, resulting in a $2.37 upside surprise. The quarter before that recorded EPS of $8.55 against expectations of $6.85, a $1.70 positive surprise. Across these three periods, Lilly exceeded consensus estimates by an average of $1.73 per share, demonstrating the company's capacity to outperform analyst models. Looking ahead, the upcoming quarter carries an analyst consensus estimate of $8.84 per share per analyst estimates, which would represent continued robust profitability if achieved.
Wall Street Analyst Ratings for LLY
Wall Street analysts maintain a uniformly bullish consensus on Eli Lilly and Company, with all five most recent ratings reaffirming positive outlooks per Wall Street analyst reports. On October 30, RBC Capital reiterated its Outperform rating, while Truist Securities maintained its Buy recommendation. Wells Fargo and Morgan Stanley both upheld Overweight ratings, and Scotiabank reiterated its Sector Outperform designation according to SID consensus data. Notably, none of the five analysts adjusted their ratings from prior assessments, reflecting sustained conviction in the company's trajectory despite the stock's substantial year-over-year gain of 33.22%. The consensus reflects confidence in Lilly's pharmaceutical pipeline, particularly its GLP-1 portfolio. The absence of any downgrades or cautionary shifts is notable given the stock's elevated valuation metrics, including a P/E ratio of 49.16 and an RSI reading of 79.9, suggesting analysts view the fundamental growth profile as supportive of current price levels.
